

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/647,841	10/05/2000	Ilga Winicov	5475-US	4329	
7:	590 01/02/2002				
Richard R. Mybeck			EXAMINER		
Post Office Box 5540 Scottsdale, AZ 85261-5540			BAUM, STUART F		
			ART UNIT	PAPER NUMBER	
			1638 DATE MAILED: 01/02/2002	ħ	
			DA LE MAILED: 01/02/2002	\mathcal{J}	

Please find below and/or attached an Office communication concerning this application or proceeding.

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, DC 20231

www.uspta.gov

APPLICATION 09/647841 CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / しいいいについ PATENT IN REEXAMINATION	ATTORNEY DOCKET NO. 5475-US
---	-------------	--	-----------------------------

Stuart Baum

ART UNIT PAPER

1638

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the one month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed Stuart Baum whose telephone number is 703-305-6997.

PRIMARY EXAMINER
GROUP 1800

		_ ·			
	Application No.	Applicant(s)			
Notic to Comply	09/647841	Art Unit			
	Examiner				
NOTICE TO COMPLY WITH REQU	Stuart Baum	1638			
CONTAINING NUCLEOTIDE SEQ					
DISCLOSURES					
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).					
The nucleotide and/or amino acid sequence the requirements for such a disclosure as					
1. This application clearly fails to compattention is directed to the final rulema OG 29 (May 15, 1990). If the effective notice published at 63 FR 29620 (June	king notice published at 55 FR filing date is on or after July 1	18230 (May 1, 1990), and 1, 1998, see the final rulemaki	114		
2. This application does not contain, as Listing" as required by 37 C.F.R. 1.821	s a separate part of the disclos (c).	ure on paper copy, a "Seque	nce		
3. A copy of the "Sequence Listing" in (37 C.F.R. 1.821(e).	computer readable form has n	ot been submitted as require	d by		
 A copy of the "Sequence Listing" in content of the computer readable form 1.823, as indicated on the attached co 	does not comply with the requ	irements of 37 C.F.R. 1.822			
5. The computer readable form that had and/or unreadable as indicated on the readable form must be submitted as re	attached CRF Diskette Proble				
6. The paper copy of the "Sequence Li "Sequence Listing" as required by 37 C		omputer readable from of the)		
7. Other:					
Applicant Must Provide: ☑ An initial or substitute computer readat	ole form (CRF) copy of the "Se	quence Listing".			
An initial or substitute paper copy of the into the specification.	e "Sequence Listing", as well a	s an amendment directing its	s entry		
☑ A statement that the content of the applicable, include no new matter, as req 1.825(d).	paper and computer readable uired by 37 C.F.R. 1.821(e) or	e copies are the same and, 1.821(f) or 1.821(g) or 1.82	where 5(b) or		
For questions regarding compliance	e to these requirements, p	elease contact:			
For Rules Interpretation, call (703)	·				
For CRF Submission Help, call (703	3) 308-4212				
PatentIn Software Program Suppor Technical Assistance		1200			
To Purchase Patentin Software					

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY